Premium
Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma‐related interstitial lung disease developed by PSGL‐1 deficient mice
Author(s) -
GonzálezSánchez Elena,
MuñozCallejas Antonio,
GómezRomán Javier,
San Antonio Esther,
Marengo Alessandro,
Tsapis Nicolas,
BohneJapiassu Kamila,
GonzálezTajuelo Rafael,
Pereda Saray,
GarcíaPérez Javier,
Cavagna Lorenzo,
GonzálezGay Miguel Ángel,
VicenteRabaneda Esther Francisca,
Meloni Federica,
Fattal Elias,
Castañeda Santos,
Urzainqui Ana
Publication year - 2022
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.15898
Subject(s) - inflammation , fibrosis , interstitial lung disease , medicine , everolimus , scleroderma (fungus) , lung , lung fibrosis , pulmonary fibrosis , disease , immunology , pathology , inoculation
Background and Purpose Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc), and current therapies available are of low efficacy or high toxicity. Thus, the identification of innovative less toxic and high efficacy therapeutic approaches to ILD treatment is an urgent need. The interaction of P‐selectin glycoprotein ligand‐1 (PSGL‐1) with P‐selectin initiates leukocyte extravasation and deletion of the corresponding gene ( Selplg ) induces a SSc‐like syndrome with high incidence of ILD in aged mice. Experimental Approach Aged PSGL‐1 KO ( Selplg ‐/‐ ) mice were used to assess the therapeutic effects of nanotherapy with everolimus, included in liposomes decorated with high MW hyaluronic acid (LipHA+Ev) and administered intratracheally to specifically target CD44‐expressing lung cells. Key Results PSGL‐1 KO mice had increased numbers of CD45+ and CD45− cells, including alveolar and interstitial macrophages, eosinophils, granulocytes and NK cells, and myofibroblasts in bronchoalveolar lavage (BAL). CD45+ and CD45− cells expressing pro‐inflammatory and pro‐fibrotic cytokines were also increased. Lungs from PSGL‐1 KO mice showed increased immune cell infiltration and apoptosis and exacerbated interstitial and peribronchial fibrosis. Targeted nanotherapy with LipHA+Ev decreased the myofibroblasts in BAL, cells producing proinflammatory and profibrotic cytokines, and the degree of lung inflammation at histology. LipHA+Ev treatment also decreased the severity of peribronchial and interstitial lung fibrosis, from moderate to mild levels. Conclusions and Implications In PSGL‐1 KO mice, targeted nanotherapy with LipHA+Ev was an effective treatment for SSc‐ILD, reducing the number of inflammatory and fibrotic cells in BAL and reducing inflammation and fibrosis in lungs.